x
Filter:
Filters applied
- Opioids
- Bharucha, Adil ERemove Bharucha, Adil E filter
- normal-transit constipationRemove normal-transit constipation filter
Publication Date
Please choose a date range between 2019 and 2019.
Keyword
- 5-HT41
- 5-hydroxytryptamine 41
- constipation-predominant IBS1
- DD1
- defecatory disorders1
- FC1
- FDA1
- Food and Drug Administration1
- functional constipation1
- gastrointestinal tract1
- GI1
- IBS1
- IBS-C1
- irritable bowel syndrome1
- NTC1
- OIC1
- opioid-induced constipation1
- PEC1
- PEG1
- percutaneous endoscopic cecostomy1
- polyethylene glycol1
- slow-transit constipation1
- STC1
Opioids
1 Results
- Thematic review on gastroenterological diseases
Chronic Constipation
Mayo Clinic ProceedingsVol. 94Issue 11p2340–2357Published online: May 1, 2019- Adil E. Bharucha
- Arnold Wald
Cited in Scopus: 84Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation.